Analyst Michael Matson from Needham reiterated a Buy rating on LivaNova and keeping the price target at $64.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Matson has given his Buy rating due to a combination of factors that highlight LivaNova’s strong financial performance and strategic advancements. The company’s second-quarter results for 2025 exceeded market expectations in both revenue and earnings per share, prompting an upward revision of its organic revenue and earnings guidance for the year. This consistent growth is evidenced by a stable organic revenue increase of over 10% compared to the previous quarter.
Furthermore, LivaNova’s Cardiopulmonary and Neuromodulation segments both surpassed consensus estimates, with notable improvement in the Neuromodulation business. Additionally, the Centers for Medicare & Medicaid Services (CMS) proposed a significant increase in reimbursement for epilepsy procedures, which could benefit LivaNova’s future revenues. The resolution of uncertainties related to Italian liabilities and tariffs, coupled with ongoing double-digit revenue growth, reinforces the positive outlook and supports the Buy recommendation.